Evidence map›Paper›PMID 41342122›Full record

ArticleEuropean journal of neurology2025

Adherence to Dual Antiplatelet Therapy Protocol in Acute Ischemic Stroke.

Laura Martikainen, Petra ljäs, Olli P Suomalainen, Liisa Tomppo, Laura Mannismäki, Henrietta Törmänen, Maria Girfanova, Sami Curtze

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Laura MartikainenDepartment of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID 0009-0009-7450-6219
Petra ljäsDepartment of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Olli P SuomalainenDepartment of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID 0000-0003-1620-051X
Liisa TomppoDepartment of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Laura MannismäkiDepartment of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID 0000-0002-3696-7219
Henrietta TörmänenDepartment of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID 0000-0002-8450-2125
Maria GirfanovaDepartment of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID 0009-0006-9958-0480
Sami CurtzeDepartment of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID 0000-0003-1545-8500

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsPrevious randomized trials, such as CHANCE and POINT, have shown that dual antiplatelet therapy (DAPT) reduces ischemic event recurrence. However, its effectiveness depends on accurate dosage and timely administration. This study is a comprehensive quality assessment of the implementation of the DAPT protocol-specifically, treatment initiation within 48 h of symptom onset in patients with mild stroke or high-risk TIA-at our center.

methodsFor this single-center, retrospective analysis we screened all 11,180 consecutive patients from the Helsinki Stroke Quality Registry (HSQR) treated at the emergency department between 1st of January 2019 and 25th of January 2023. Patients with DAPT (ASA and clopidogrel) within 2 weeks of admission were included. Patients treated with i.v. thrombolysis, thrombectomy or if already on DAPT prior to admission were excluded. We analyzed the time of DAPT initiation, patient diagnoses and risk scores (NIHSS and ABCD

resultsOf 11,180 patients screened, 299 met the inclusion criteria. Among them, 263 (88.0%) had a final diagnosis of ischemic stroke or TIA, supporting DAPT use. Risk scores were documented in 193 (73.4%), and 197 (65.9%) initiated DAPT within 48 h of symptom onset per our institutional protocol. Overall, 137 (45.8%) fully adhered to all protocol criteria.

conclusionsFewer than half (45.8%) of patients fully adhered to the HUS protocol, and 65.9% initiated DAPT within 48 h from symptom onset. We propose that DAPT should be considered as part of the acute stroke treatment protocol for eligible patients to minimize delays in treatment initiation.

Indexed as

AspirinClopidogrelDual Anti-Platelet TherapyGuideline AdherenceIschemic StrokePlatelet Aggregation InhibitorsAgedAged, 80 and overFemaleHumansIschemic Attack, TransientMaleMiddle AgedRegistriesRetrospective StudiesAspirinClopidogrelPlatelet Aggregation Inhibitorsdual antiplatelet therapy (DAPT)ischemic stroke and TIAtreatment adherence and quality assessment

Identifiers

PMID41342122
PMCPMC12676178

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.